Biocept (NASDAQ:BIOC) Coverage Initiated at StockNews.com

Posted by on Apr 12th, 2023

Analysts at StockNews.com initiated coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, Brookline Capital Management downgraded Biocept from a “buy” rating to a “hold” rating in a report on Friday, January 6th.

Biocept Stock Performance

NASDAQ:BIOC opened at $0.32 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.86 and a current ratio of 5.13. The firm has a market cap of $5.46 million, a PE ratio of -0.33 and a beta of 0.94. The business has a 50 day moving average price of $0.43 and a 200-day moving average price of $0.61. Biocept has a fifty-two week low of $0.24 and a fifty-two week high of $2.05.

Institutional Trading of Biocept

An institutional investor recently raised its position in Biocept stock. Renaissance Technologies LLC raised its holdings in Biocept, Inc. (NASDAQ:BIOC – Get Rating) by 50.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 175,500 shares of the medical research company’s stock after purchasing an additional 59,100 shares during the quarter. Renaissance Technologies LLC owned 1.04% of Biocept worth $165,000 as of its most recent SEC filing. 10.04% of the stock is currently owned by institutional investors.

About Biocept

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.

Featured Articles

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.